Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.

PLoS One · 2012 · PMC3420911 · PMID 22916113

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Overall AE (3732 patients, 78% vs 75%; OR 1.20 [0.97–1.49], REM; 6 RCTs) showed a trend towards higher rates with telavancin, whereas serious AE (3732 patients, 17% vs 13%; OR 1.38 [0.90–2.13], REM; 6 RCTs; figure 3C ) were comparable between telavancin and vancomycin recipients.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.